Advice
following a full submission assessed under the orphan medicine process:
etelcalcetide (Parsabiv®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
In a phase III study, etelcalcetide was at least as effective as another calcimimetic in reducing parathyroid hormone levels.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by the SMC.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice344KB (PDF)
Medicine details
- Medicine name:
- etelcalcetide (Parsabiv)
- SMC ID:
- 1262/17
- Indication:
- Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 11 September 2017